Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Looking at options history for Vertex Pharmaceuticals (NASDAQ: VRTX) we detected 10 trades. If we consider the specifics of ...

Over the past six months, Vertex Pharmaceuticals’s stock price fell to $413.23. Shareholders have lost 12.5% of their capital ...

Vertex Pharmaceuticals (VRTX) shares saw mild movement today, with the stock ticking slightly higher over the past week.

Vertex Pharmaceuticals’ CRISPR-based therapy made history as the first drug of its type, transforming care options for sickle ...

We expect Vertex Pharmaceuticals VRTX to surpass expectations when it reports its second-quarter 2025 results on Aug. 4, after market close. The Zacks Consensus Estimate for the to-be-reported quarter ...

Vertex's revenue was $2.96 billion in the second quarter of 2025, beating the consensus forecast by $58 million. Click here ...

Vertex faces pressure from potential U.S. drug pricing reforms and tariffs. Click here to find out why VRTX stock is a Hold.

Vertex is defying the bear market, up 30% so far this year. The company is a leader in the cystic fibrosis market and generates billions of dollars annually from its treatments for that condition.

Vertex, Inc. (NASDAQ:VERX), a leading global technology provider of indirect tax solutions, today announced that it will release third quarter 2025 financial results before the market opens on Monday, ...